Brought to you by 
Eddingpharm gets license to Ablynx's ALX0141 in the Greater China region; deal expanded to include Phase II RA candidate
06 May 2020
Executive Summary
Antibody therapeutics developer Ablynx NV licensed specialty pharmaco Eddingpharm International Holdings Ltd. exclusive rights to develop and commercialize ALX0141 in China, Hong Kong, Macau, and Taiwan for all indications, including osteoporosis and bone metastases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eddingpharm gets license to Ablynx's ALX0141 in the Greater China region; deal expanded to include Phase II RA candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice